順豐控股(002352.SZ):招廣投資非公開發行可交債獲深交所無異議函
格隆匯5月20日丨順豐控股(002352.SZ)公佈,公司於2020年5月20日收到持股5%以上股東深圳市招廣投資有限公司(以下簡稱“招廣投資”)的書面通知,獲悉招廣投資已收到深交所出具的《關於深圳市招廣投資有限公司2020年非公開發行可交換公司債券符合深交所轉讓條件的無異議函》。招廣投資以其持有的公司部分股票為標的,非公開發行面值不超過50億元人民幣的可交換公司債券符合深交所掛牌轉讓條件,深交所對其掛牌轉讓申請無異議。
截至本公告披露之日,招廣投資持有公司2.67億股,佔公司總股本的6.04%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.